Managing cancer during pregnancy requires balancing effective maternal treatment against potential fetal risks, according to recent clinical guidance. While the placenta acts as a selectively permeable barrier, it does not completely block medications, allowing certain chemotherapy agents to cross into fetal circulation (Tetro et al., 2018). Understanding how these drugs transfer across the placenta is critical for oncologists, maternal-fetal medicine specialists, and obstetricians when designing treatment plans that protect both mother and child (Gulersen et al., 2026).
Mechanisms of Placental Drug Transfer During Cancer Treatment
The placenta regulates the exchange of substances between maternal and fetal circulations through several transport mechanisms. According to Myllynen et al. (2007) and Tetro et al. (2018), passive diffusion along a concentration gradient serves as the primary route for many drugs. However, facilitated diffusion, active transport, and carrier-mediated processes also influence drug transfer.
Fetal exposure cannot be predicted solely by measuring maternal drug concentrations. Some compounds accumulate directly within placental tissue, altering how the organ develops and functions (Tetro et al., 2018). Benoit et al. (2021) and Depoix et al. (2020) note that chemotherapy can trigger indirect fetal effects by disrupting placental vascularization, metabolism, and nutrient transport, making drug selection a nuanced, agent-specific decision.
Chemotherapy Classes and Their Transplacental Passage
Placental transfer rates vary widely across different chemotherapy classes and even among individual drugs within the same class (Berveiller et al., 2016). Anthracyclines, taxanes, alkylating agents, and platinum compounds each interact differently with the placental barrier.
- Anthracyclines: Doxorubicin and epirubicin have well-established safety profiles in clinical practice and can be used during the second and third trimesters with limited fetal exposure compared to other agents in their class (Nanda et al., 2025). Conversely, idarubicin exhibits high lipophilicity and increased placental permeability linked to fetal cardiotoxicity, rendering it unsuitable for use during pregnancy (Benoit et al., 2021). Daunorubicin is generally preferred over idarubicin for specific hematologic malignancies during later trimesters.
- Taxanes: Paclitaxel and docetaxel demonstrate relatively low transplacental transfer during ex vivo human placental perfusion studies, largely driven by high protein binding and placental transporter activity (Berveiller et al., 2012). These agents are increasingly utilized in breast cancer treatment protocols after the first trimester (Nanda et al., 2025).
- Alkylating Agents: Cyclophosphamide crosses the placenta and can cause DNA damage, yet it remains a component of carefully timed regimens during the second and third trimesters when clinically required (Berveiller et al., 2016).
Did You Know?
Placental transfer is not uniform across chemotherapy drugs. Even two drugs from the exact same pharmacological class can exhibit vastly different rates of transplacental passage based on molecular size, lipid solubility, and protein binding, according to Berveiller et al. (2016).
Gestational Timing and Associated Fetal Risks
The timing of chemotherapy exposure dictates the severity and nature of fetal risks. According to van Gerwen et al. (2021), initiating chemotherapy before 12 weeks of gestation—during the critical window of organogenesis—carries the highest risk of miscarriage and major congenital malformations.
Administering chemotherapy during the second and third trimesters significantly reduces the risk of major structural anomalies. However, Nanda et al. (2025) and Gulersen et al. (2026) report that later exposure can still lead to fetal growth restriction, low birth weight, preterm birth, and transient neonatal myelosuppression. Encouragingly, long-term pediatric follow-up studies indicate that cognitive, cardiac, and developmental outcomes are generally reassuring, with prematurity acting as a more prominent factor in neurodevelopmental challenges than prenatal chemotherapy exposure itself (Amant et al., 2015).
Multidisciplinary Clinical Guidance and Delivery Planning
Current medical consensus dictates that effective cancer treatment should not be delayed or withheld solely due to pregnancy (Loren et al., 2026). When appropriate, oncologists defer systemic therapy until after the first trimester. While many cytotoxic regimens are safely administered during subsequent trimesters, methotrexate is strictly contraindicated due to severe embryotoxic and teratogenic effects (Loren et al., 2026).
Targeted therapies—including endocrine therapies, HER2-targeted agents, VEGF inhibitors, PARP inhibitors, antibody-drug conjugates, and cellular therapies—remain contraindicated during pregnancy due to established fetal risks and insufficient safety data (Loren et al., 2026). To allow adequate time for maternal and fetal bone marrow recovery, clinicians typically discontinue most chemotherapy regimens by approximately 34 weeks of gestation, aiming to avoid delivery before 37 weeks unless indicated by obstetric complications (Gulersen et al., 2026).
Pro Tip:
Continuous maternal and fetal monitoring—including serial growth assessments, comprehensive obstetric evaluations, and coordinated delivery planning between oncology and neonatology teams—is essential for optimizing outcomes (Gulersen et al., 2026).
Frequently Asked Questions
Can chemotherapy cross the placenta?
Yes. Many chemotherapy medications cross the placenta to varying degrees, depending on the specific drug’s chemical properties and placental transport mechanisms.
When is chemotherapy most dangerous during pregnancy?
The first trimester presents the highest risk of miscarriage and major congenital malformations because major organs are actively forming during this window (van Gerwen et al., 2021).
Can chemotherapy be given during the second and third trimesters?
Yes. Several established chemotherapy regimens can be administered safely during the second and third trimesters when medically necessary, though close fetal monitoring is required (Gulersen et al., 2026).
Which cancer drugs must be avoided entirely during pregnancy?
Methotrexate is contraindicated due to its severe teratogenic effects. Additionally, endocrine therapies, HER2-targeted treatments, VEGF inhibitors, and PARP inhibitors must be avoided because of known fetal risks (Loren et al., 2026).
What are the long-term developmental outcomes for children exposed to chemotherapy in utero?
Available studies show generally reassuring cognitive, cardiac, and growth outcomes, with prematurity being a stronger predictor of developmental complications than the chemotherapy exposure itself (Amant et al., 2015).
Join the Conversation
Have questions about managing complex medical conditions during pregnancy? Share your thoughts in the comments below, explore our related articles on oncology care, and subscribe to our newsletter for the latest clinical updates.
Worth a look